{"id":823107,"date":"2025-03-07T09:28:08","date_gmt":"2025-03-07T14:28:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/"},"modified":"2025-03-07T09:28:08","modified_gmt":"2025-03-07T14:28:08","slug":"capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/","title":{"rendered":"Capricor Therapeutics to Present at Leerink\u2019s Global Healthcare Conference 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, March  07, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hqwGEOXcbNgm4Z5ssxTQf2cm59tsZzLbMsPMa3yxuUfmYR_wPQq_SsY-7zmHhwZm5zinU9geVKcwjbZqkVf1EPHcTOMpOgUcp0E4rDM54Fs=\" rel=\"nofollow\" target=\"_blank\"><u>Capricor Therapeutics<\/u><\/a> (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that Capricor management will participate in one-on-one investor meetings and provide a corporate update at Leerink\u2019s Global Healthcare Conference 2025, taking place March 10-12, 2025 in Miami, Florida.<\/p>\n<p align=\"justify\">\n        <strong>Leerink\u2019s Global Healthcare Conference 2025<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>Presentation Date:<\/strong>\u00a0Wednesday, March 12, 2025<\/li>\n<li style=\"text-align:justify\">\n          <strong>Time:<\/strong>\u00a01:00-1:40 p.m. ET<\/li>\n<li style=\"text-align:justify\">\n          <strong>Webcast:<\/strong><br \/>\n          <a href=\"https:\/\/wsw.com\/webcast\/leerink38\/register.aspx?conf=leerink38&amp;page=capr&amp;url=https:\/\/wsw.com\/webcast\/leerink38\/capr\/2208062\" rel=\"nofollow\" target=\"_blank\"><br \/>\n            <u>Click here<\/u><br \/>\n          <\/a><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">Capricor management will present updates on its lead program of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) as well as provide other general scientific and corporate updates. For further information on this presentation, please visit Capricor&#8217;s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=laNTkpNDO0-AQwBaPIgJ0UB23VkDxB3m2dwF_y5R_bJGOfNheNgKVr98I4niNQD3G7UA_E3bA2vvBUyytaqAKu6B5ECKj8IcKc7dYETHU5g-5E-4KYBbplj1Dnuk7hEuG36yzwroEUjqYh8EbhGZvNhxF8B9MAHJX0KDRaj2qX8FjyskEiNpXgBkUqcbqnU8VDqUb_nGoKEw47jkewQuJGaeyF5zdDaRAFb3AO68OFT_VxPmt5EVDKQCJBpNko72bfhu4bjkOillH6t90WmKoi4iGNgBSvqaHpLTq4sdkeIoV_rWtSsLDQl19YltxvB5CE3qJKN5zYr_zSeohpXkGa0hOnnVOzKyOlQnZg08T75sFPkxdUcjTSYTINTaibmwD2DJzW8LWPZ2fG6ixhXQxWM0Xw0rHhgK42BfwTqrJRQGf8B20JGHXGKwC6wAphWn5AJH4vtZ51e16bf9apL59SZ-zgkA2ZVpsHhF2msnmnHYGH7fDQVMgW22d8wy0OFav_a3Glo7uJ4PBLP8YSfvOl4ZMfxmG17fpGK2CmXL8KvG-PDbKRrBxb2juXD_AAtz\" rel=\"nofollow\" target=\"_blank\"><u>http:\/\/capricor.com\/news\/events\/<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Capricor Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel, an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently in late-stage development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX\u2122 platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NooyNV2BbV9NXn5KHVfrBVVGAfq8ahgqzDu_4UgWfKHeGKS09ut3FaWA77bMBidxSGnCq8oWppYb2Q4-7GtPoJMjl51yACbWgInR2gbtYVnD8ll6-_lPa4tecCqavgFFOfAjIl1hSkWK8Z8oHylXX0tbmrecbnan6hegTV6jrU5Xdo-kk7G8UmqU8G22r_QeFLe9dtKrzQPIa1J-5AA-jpEO3wHGAVh_RM220t8ZIMZh20yBFo6yk1ySX23Jrj_aCS6ScrPmNEUudhFCe5HOMA1D3KobHA62FOcbhAzTZEMI8X0AcLsaGFw8CmliI0wSI2fpbZJgT8qMn6OjZYYhGvWJCozfaEv4KM0IXtDLQrOMtLeeVg9Z497GmyTsYEv2TsuQd0lIR_OyPtW6NYtN8tHKVJ-eLkXCIFyQI0E1kiWN5oqzq-6RFCCP5XsIL41rv6B4-4FSOYlWQ4iuPaNaicdQMGk7jij__f2ewnrxuVoqWPfmEm9THpdoyUsCq6H3cIQ0ETlczaTVWP3cAhyYWAfdAjWwOhzca96qKXNHwsuR_lGGNtNuWKwPbUkM8Tqov1eK2XD3YP6dZaYkHv5bI_DX8N19fg1HSuun-3Y1Hd3tCEspIxn-LPXnchy4b-nfw2M5BrMGXB0zoqj4F28jS84QbWXgfs4acI5TeWMUW3c=\" rel=\"nofollow\" target=\"_blank\"><u>capricor.com<\/u><\/a>, and follow Capricor on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K2b58QrNCob-lXJvCEgVUsmXk5xnjejynWy0jYSj47Rs2u0pH01TiQU5Vi2KE3-qmH_lHfOAXEaStJHGKdF6P8SS1EOFzHQeeZHY54Xxpcn1J-5jlX-Ii3zpiXq55rtDmvMuUBrnLzrDCQSba0__uK3N-eRXVzIx_j2ZjvPj-10hqSBFQYelbgOBBILXcAa9dNnNB1NBsZFI3W6kN5HJ_YdGLqHpkuEXeqlCbds36ivzkWcOEDh70IkYGWHw1VVgKd5RBB6JePC0Wk6AgHT-SG6CsU3-f_i4S-CY-eNJzJYZ2CsIKTQy9IAQugv8NPHqPsrFjvkFkm9RrGyFlCmAeisQq82gDR10pnDL3Fnn-GvDaWyXT8rk6-qV7fzpB8kwHjufTyewL4c7OyIRWtou-DOeP3KQLra9Wkl4qUO7xlFlG6zmVMjqNA3URzp3Kqp-5osJV5CMVmu-t6bhb2iyW2YQbFVKuP6RG6p5ghdze8oXGTTFxOSoJTLv-k67rrTjPug1lmg0tdRwp9R0UUp9g77jlyDEYI73XscvTBzu0q1LZlFxCN63Y0EeP3fyj4V52WfHcPS5z86y2EogrI9JPidymmnwWbAuPPZEPFu0fN1a8UNg_0ATCiS3jY6X62gKXXSqWx0hxtXR4NTtT99k57ltAu5koJr7SJk32kE-ho3oST2jgcQgp5twHcssoJe9\" rel=\"nofollow\" target=\"_blank\"><u>Facebook<\/u><\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9FjT97s4jTI7fXVXHs9RHx-QCPYWSpCT9Qc7HpxouZ0iKDV_SeUGrwKdL8p0mn9_2k_MdCCexss_vfLnEH5lAL1mxwXTN0l8oyOdxl-epamOMoxc1xeUvoXWSej6PHFYuS_AjApEkVDGYEeZPzLqrozWbS_ixh2mbxYSayEnmPr1C0a12cOXbpFm77K94UtxdLP-RT0w8naFVPAsjzMNwn2g8RTdwglkcHvTQMs8FWnN1zuotYf6Tti_Am1S1NYagABaBsP9ntjIhcECP1QouaI1vPEJsnGGAqiawUeuVMZ9DSHDLSTeNVsTi-eJE95nEwIRTSX6pgs7T-xCrly8sUeX2AJ2pgKtlz-OFzTFnOI_Jo9FRPI3Hab5IbZ15rasKZNA1S0Eh_hXV0C7Eey6a-roOmVk0SiDEBi-CEVMQJyE2YD50zTYPrMCagEeIqNwPOAp7nQEzKP4JoHIw8uh2P4qS8D58yvEVQeN-keNXK4wx3aFGxsRXyBMuR5xNCd4AFvxGxn9yxgrpMyO2Dxp0H04JouN7jzA5JNLWQ82MUHdY8gJsnclBNNVHprfGc5mV8wH-mTYyWYz3UsqGnOgOYhx61nLkN7n8bp_T9f9PdvmRFFOF37Jb1KX0Ld4XnfUOXaKKmkEc9CGU78xCK-hzC-Av2KnGlwUxYUTQFhYp2Kyl07n4x0HCjdC5NZW2PVE\" rel=\"nofollow\" target=\"_blank\"><u>Instagram<\/u><\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=khZjEQ1-hyGUyBlRZv962CS42urI7yLuEDPMxuIwoUCthqT43N7IjUwhOttQBl5Dik2pCFIEm7jYRsZzmWITSR7JMrz1Ia3_AtbtCcdbETbLL3x0jcAxT90EJLed36Yj8ouJ4QAlNvVG11iPn1iTsgRp4DqNqDdt3D2m9PER427yDryDtFK8jLuDtzv18BffDwFE3w1uJoa_eLPBtF522w0ZUh3OXsYW0_8zoN2Gliuj3gtIo9act15fD-XsVByKVAUbcnAABi8NhiD_3Ko9kJ_l715Zro8lO2gJh-jz2HOTm6TuCobVLGgdjvwoKBPrlQ_haaa7lbIqNDciz7D0jtfPP5i5zeabktBCLh7sZvpNRP812ulTJ64TmX_rFmnUox8rcxdzA_dEN6yB29qyCaDiFGQgFUH5Hd5H0V8pIHBggtrJDAUhMPPAmQrSkUjehPM55dvrrwRNf41VCpuVHKQeJetQDXB7j3CiLIC-kBZ1ZNe8f60KQ1f-8CAlGN8C6cyi96UWNOz-luZERi5Q-lSXVHIkU7WD8AnMlm1VGsQFl-cSZ71EQJv_k3f5X2UJd9QJ55kzlD-9RvB71F2uJpnzjeKQb3g1DTQBa5oqOuqSFRtplI9u18jNJN_OhKvlA80A9opOHhru8CoBbI6sIkYu5SbEz_8DaTiQZyVMH_o=\" rel=\"nofollow\" target=\"_blank\"><u>Twitter<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor\u2019s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; statements about our financial outlook; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; potential future agreements; scope, duration, validity and enforceability of intellectual property rights; future revenue streams and projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor\u2019s management team\u2019s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words \u201cbelieves,\u201d \u201cplans,\u201d \u201ccould,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cestimates,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor\u2019s business is set forth in Capricor\u2019s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 11, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on November 14, 2024. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.<\/p>\n<p align=\"justify\">Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel is an Investigational New Drug and is not approved for any indications. None of Capricor\u2019s exosome-based candidates have been approved for clinical investigation.<\/p>\n<p align=\"justify\">\n        <strong>For more information, please contact:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Capricor Media Contact:<\/strong><br \/>\n        <br \/>Raquel Cona<br \/>KCSA Strategic Communications <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L608TwvljMYSIMyl-vLSPO3cP0Wo3D4c-bP_1HcABXFHOZ-7UmsADk-gHuyoLUY1LjqsZA7XjJ57aVLmyiuwnw==\" rel=\"nofollow\" target=\"_blank\"><u>rcona@kcsa.com<\/u><\/a><br \/>212.896.1204<\/p>\n<p align=\"justify\">\n        <strong>Capricor Company Contact:<\/strong><br \/>\n        <br \/>AJ Bergmann, Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lKUYgv06-dUWu3kIFNX5f-LyZsdBYScrcKbUp7pOJIybbBxeVH27S_eBFP7qTZALyeExcKkqMIrF8I9Yw6ynSHkdjGZVqs1OaJakkpsS2dg=\" rel=\"nofollow\" target=\"_blank\"><u>abergmann@capricor.com<\/u><\/a><br \/>858.727.1755<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MDY1OCM2Nzk1Mjk0IzUwMDA2ODU2Ng==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Mjg5M2U5MjEtOTFiMC00YjYxLTljNzgtZjQ3ZmY4MzRlNzZmLTUwMDA2ODU2Ng==\/tiny\/Capricor-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) &#8212; Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that Capricor management will participate in one-on-one investor meetings and provide a corporate update at Leerink\u2019s Global Healthcare Conference 2025, taking place March 10-12, 2025 in Miami, Florida. Leerink\u2019s Global Healthcare Conference 2025 Presentation Date:\u00a0Wednesday, March 12, 2025 Time:\u00a01:00-1:40 p.m. ET Webcast: Click here Capricor management will present updates on its lead program of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) as well as provide other general scientific and corporate updates. For further information on this presentation, please visit Capricor&#8217;s website at\u00a0http:\/\/capricor.com\/news\/events\/. About Capricor Therapeutics Capricor Therapeutics, Inc. (NASDAQ: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Capricor Therapeutics to Present at Leerink\u2019s Global Healthcare Conference 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-823107","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Capricor Therapeutics to Present at Leerink\u2019s Global Healthcare Conference 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Capricor Therapeutics to Present at Leerink\u2019s Global Healthcare Conference 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) &#8212; Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that Capricor management will participate in one-on-one investor meetings and provide a corporate update at Leerink\u2019s Global Healthcare Conference 2025, taking place March 10-12, 2025 in Miami, Florida. Leerink\u2019s Global Healthcare Conference 2025 Presentation Date:\u00a0Wednesday, March 12, 2025 Time:\u00a01:00-1:40 p.m. ET Webcast: Click here Capricor management will present updates on its lead program of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) as well as provide other general scientific and corporate updates. For further information on this presentation, please visit Capricor&#8217;s website at\u00a0http:\/\/capricor.com\/news\/events\/. About Capricor Therapeutics Capricor Therapeutics, Inc. (NASDAQ: &hellip; Continue reading &quot;Capricor Therapeutics to Present at Leerink\u2019s Global Healthcare Conference 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-07T14:28:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MDY1OCM2Nzk1Mjk0IzUwMDA2ODU2Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Capricor Therapeutics to Present at Leerink\u2019s Global Healthcare Conference 2025\",\"datePublished\":\"2025-03-07T14:28:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\\\/\"},\"wordCount\":699,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MDY1OCM2Nzk1Mjk0IzUwMDA2ODU2Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\\\/\",\"name\":\"Capricor Therapeutics to Present at Leerink\u2019s Global Healthcare Conference 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MDY1OCM2Nzk1Mjk0IzUwMDA2ODU2Ng==\",\"datePublished\":\"2025-03-07T14:28:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MDY1OCM2Nzk1Mjk0IzUwMDA2ODU2Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MDY1OCM2Nzk1Mjk0IzUwMDA2ODU2Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Capricor Therapeutics to Present at Leerink\u2019s Global Healthcare Conference 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Capricor Therapeutics to Present at Leerink\u2019s Global Healthcare Conference 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/","og_locale":"en_US","og_type":"article","og_title":"Capricor Therapeutics to Present at Leerink\u2019s Global Healthcare Conference 2025 - Market Newsdesk","og_description":"SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) &#8212; Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that Capricor management will participate in one-on-one investor meetings and provide a corporate update at Leerink\u2019s Global Healthcare Conference 2025, taking place March 10-12, 2025 in Miami, Florida. Leerink\u2019s Global Healthcare Conference 2025 Presentation Date:\u00a0Wednesday, March 12, 2025 Time:\u00a01:00-1:40 p.m. ET Webcast: Click here Capricor management will present updates on its lead program of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) as well as provide other general scientific and corporate updates. For further information on this presentation, please visit Capricor&#8217;s website at\u00a0http:\/\/capricor.com\/news\/events\/. About Capricor Therapeutics Capricor Therapeutics, Inc. (NASDAQ: &hellip; Continue reading \"Capricor Therapeutics to Present at Leerink\u2019s Global Healthcare Conference 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-07T14:28:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MDY1OCM2Nzk1Mjk0IzUwMDA2ODU2Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Capricor Therapeutics to Present at Leerink\u2019s Global Healthcare Conference 2025","datePublished":"2025-03-07T14:28:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/"},"wordCount":699,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MDY1OCM2Nzk1Mjk0IzUwMDA2ODU2Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/","name":"Capricor Therapeutics to Present at Leerink\u2019s Global Healthcare Conference 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MDY1OCM2Nzk1Mjk0IzUwMDA2ODU2Ng==","datePublished":"2025-03-07T14:28:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MDY1OCM2Nzk1Mjk0IzUwMDA2ODU2Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MDY1OCM2Nzk1Mjk0IzUwMDA2ODU2Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-at-leerinks-global-healthcare-conference-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Capricor Therapeutics to Present at Leerink\u2019s Global Healthcare Conference 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/823107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=823107"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/823107\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=823107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=823107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=823107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}